| | Variables | Eosinophil count ≥300 (n = 90) | Eosinophil count <300 (n = 86) |
| | Age (year), mean ± SD | 67.4 ± 8.9 | 67.7 ± 12.0 | | BMI (kg/m2), mean ± SD | 24.4 ± 7.3 | 26.6 ± 7.5 | | Gender, n (%) | | | | Female | 42 (46.7) | 37 (43.0) | | Male | 48 (53.3) | 49 (57.0) | | Current smoking status, n (%) | | | | Smoker | 13 (14.4) | 10 (11.6) | | Pack-year | 50.1 (25.1) | 58.7 (23.0) | | Vaccination history, n (%) | | | | Influenza vaccine | 79 (87.8) | 80 (93.0) | | Pneumococcal vaccine | 66 (73.3) | 54 (62.8) | | COPD treatment, n (%) | | | | SABA | 87 (96.7) | 79 (91.9) | | SAMA | 6 (6.7) | 5 (5.8) | | ICS/LABA | 80 (88.9) | 70 (81.4) | | LAMA | 81 (90.0) | 72 (83.7) | | PDE4 inhibitor | 3 (3.3) | 2 (2.3) | | Systemic corticosteroids | 19 (21.1) | 22 (25.6) | | Macrolides | 4 (4.4) | 5 (5.8) | | Home O2 therapy | | | | Yes | 58 (64.4) | 45 (52.4) | | Walking aids, n (%) | | | | Yes | 54 (60.0) | 39 (45.3) | | pCO2 retainer, n (%) | | | | Yes | 39 (43.3) | 34 (39.6) | | CO2 level (mmHg), mean ± SD | 45.2 ± 8.1 | 45.9 ± 10.1 | | BODE index, mean ± SD | 5.8 ± 2.1 | 5.5 ± 2.1 | | 6MWT (m), mean ± SD | 242.9 ± 105.9 | 247.3 ± 110.4 | | FEV1 (%), mean ± SD | 35.5 ± 30.1 | 36.9 ± 16.7 | | Dyspnea mMRC scale, n (%) | | | | 0 | 3 (3.5) | 2 (2.5) | | 1 | 6 (7.1) | 11 (13.6) | | 2 | 33 (38.8) | 28 (32.6) | | 3 | 18 (21.2) | 22 (25.6) | | 4 | 24 (28.2) | 18 (20.9) |
|
|
Data are presented as mean ± SD (standard deviation), n (number), or % (percentage). Pack-year is calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked. SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; ICS/LABA, inhaled corticosteroid/long-acting β-agonist; LAMA, long-acting muscarinic antagonist; PDE4, phosphodiesterase type 4; O2, oxygen; pCO2, partial pressure of carbon dioxide; mmHg, millimeter mercury; BODE, body mass index, airflow obstruction, dyspnea, and exercise; 6MWT, 6-minute walk test; m, meter; mMRC, modified Medical Research Council.
|
